Cabaletta Bio 3Q 2026: EPS ($0.28) — 10-Q Summary
Cabaletta Bio reported no revenue in Q3 2026, with a net loss of $53.05M, widening from $44.87M a year ago. R&D costs rose $7.3M, driven by higher manufacturing and clinical-trial expenses. The company is advancing clinical trials and expects to update plans in early 2027. According to the company, manufacturing partners include Lonza, ElevateBio, and Cellares.
How this was made
The 30-second read
Why it matters
The Q3 loss widens, indicating higher cash burn, which could trigger short‑term selling pressure.
Market read
Earnings release provides fresh data for traders; likely short‑term downside for the stock.
What to watch
Potential future revenue from upcoming clinical trials not reflected in this quarter.
Background
Cabaletta Bio is a clinical‑stage biotech focusing on rare autoimmune diseases.
Ticker impact
Cabaletta Bio reported Q3 2026 net loss of $53.05M, EPS -$0.28 and no revenue, widening loss year over year.
downward pressure as market prices in the larger loss and lack of revenue
The company posted a larger net loss than the prior quarter and no revenue, which typically triggers sell‑offs in micro‑cap biotech stocks.
Market effects
Biotech sector may see slight negative sentiment as a peer reports widened losses.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the company’s pipeline advances, the loss may be viewed as a short‑term pain for long‑term upside.
Key entities
- companyCabaletta Bio
Clinical‑stage biotech (ticker CABA).